<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87502">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02110251</url>
  </required_header>
  <id_info>
    <org_study_id>PEARL study</org_study_id>
    <nct_id>NCT02110251</nct_id>
  </id_info>
  <brief_title>Exercise Therapy With Risk Factor Management and Life Style Coaching After Vascular Intervention for Patients With Peripheral Arterial Disease</brief_title>
  <acronym>PEARL</acronym>
  <official_title>Exercise Therapy With Risk Factor Management and Life Style Coaching After Vascular Intervention for Patients With Peripheral Arterial Disease With Critical Limb Ischemia or Tissue Loss. A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catharina Ziekenhuis Eindhoven</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with peripheral arterial disease with symptoms of critical ischemia or reduced
      tissue loss have a very high mortality and morbidity rate. So far, treatment strategies
      focused on the preservation of life and limb by an open surgical or endovascular
      revascularization, together with cardiovascular risk management and pain relief. Important
      modifiable factors related to mortality and morbidity are not covered in the current
      national and international guidelines. This study investigates the effects on mobility,
      mortality and quality of life with supplementation of the standard treatment of critical
      limb ischemia  with supervised exercise therapy. Also a reduction of cardiovascular risk by
      intensive risk factor management and lifestyle coaching will be taken in to account. The
      supervised exercise therapy will take place under the supervision of a trained
      physiotherapist.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mobility</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain free walking distance WIQ ALDS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>RAND SF 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Peripheral Arterial Disease, Rutherford Stage 4 and 5 With the Possibility to Improve Vascularization.</condition>
  <arm_group>
    <arm_group_label>Supervised exercise therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adequacy of initial therapy, Investigation degree of confusion and dementia, Preoperative preparation, Life-style coaching, Supervised Exercise therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Walking advice</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care and a oral walking advice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Supervised Exercise Therapy</intervention_name>
    <arm_group_label>Supervised exercise therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with peripheral arterial disease Rutherford stage 4 and 5, where it is
             possible to improve the vascularization of the affected leg with the help of an
             endovascular and / or open surgical vascular intervention.

          -  Patients with both legs are affected, but the most severe leg does not exceed stage
             5.

        Exclusion Criteria:

          -  Severe cardiopulmonary comorbidity (NYHA 4) and previous amputations of lower leg or
             thigh.

          -  Patients with limited amputation of the toes can participate.

          -  Insufficient understanding of the Dutch language.

          -  No physiotherapy insurance.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joep Teijink, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Ziekenhuis Eindhoven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edith Willigendael</last_name>
    <phone>0032 72-5482432</phone>
    <email>E.M.Willigendael@mca.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regine van Grinsven, MSc</last_name>
      <phone>0031 40 2396349</phone>
      <email>regine.v.grinsven@catharinaziekenhuis.nl</email>
    </contact>
    <contact_backup>
      <last_name>Nicole Verhofstad, Dr</last_name>
      <phone>0031 40 2396349</phone>
    </contact_backup>
    <investigator>
      <last_name>Joep Teijink</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Alkmaar</name>
      <address>
        <city>Alkmaar</city>
        <zip>1815 JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Bakker, MD</last_name>
      <phone>0032 72 548 4444</phone>
      <email>N.Bakker2@mca.nl</email>
    </contact>
    <investigator>
      <last_name>Edith Willigendael, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>April 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catharina Ziekenhuis Eindhoven</investigator_affiliation>
    <investigator_full_name>Joep Teijink</investigator_full_name>
    <investigator_title>prof. dr.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
